Literature DB >> 24952653

Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality.

Marguerite R Irvin1, John N Booth2, Daichi Shimbo3, Daniel T Lackland4, Suzanne Oparil5, George Howard6, Monika M Safford7, Paul Muntner2, David A Calhoun5.   

Abstract

Apparent treatment-resistant hypertension (aTRH) is defined as uncontrolled hypertension despite the use of three or more antihypertensive medication classes or controlled hypertension while treated with four or more antihypertensive medication classes. We evaluated the association of aTRH with incident stroke, coronary heart disease (CHD), and all-cause mortality. Participants from the population-based REasons for Geographic And Racial Differences in Stroke (REGARDS) Study treated for hypertension with aTRH (n = 2043) and without aTRH (n = 12,479) were included. aTRH was further categorized as controlled aTRH (≥4 medication classes and controlled hypertension) and uncontrolled aTRH (≥3 medication classes and uncontrolled hypertension). Over a median of 5.9, 4.4, and 6.0 years of follow-up, the multivariable adjusted hazard ratio for stroke, CHD, and all-cause mortality associated with aTRH versus no aTRH was 1.25 (0.94-1.65), 1.69 (1.27-2.24), and 1.29 (1.14-1.46), respectively. Compared with controlled aTRH, uncontrolled aTRH was associated with CHD (hazard ratio, 2.33; 95% confidence interval, 1.21-4.48), but not stroke or mortality. Comparing controlled aTRH with no aTRH, risk of stroke, CHD, and all-cause mortality was not elevated. aTRH was associated with an increased risk for coronary heart disease and all-cause mortality.
Copyright © 2014 American Society of Hypertension. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Resistant hypertension; antihypertensives; outcomes; severe hypertension

Mesh:

Substances:

Year:  2014        PMID: 24952653      PMCID: PMC4120268          DOI: 10.1016/j.jash.2014.03.003

Source DB:  PubMed          Journal:  J Am Soc Hypertens        ISSN: 1878-7436


  32 in total

1.  Case definitions for acute coronary heart disease in epidemiology and clinical research studies: a statement from the AHA Council on Epidemiology and Prevention; AHA Statistics Committee; World Heart Federation Council on Epidemiology and Prevention; the European Society of Cardiology Working Group on Epidemiology and Prevention; Centers for Disease Control and Prevention; and the National Heart, Lung, and Blood Institute.

Authors:  Russell V Luepker; Fred S Apple; Robert H Christenson; Richard S Crow; Stephen P Fortmann; David Goff; Robert J Goldberg; Mary M Hand; Allan S Jaffe; Desmond G Julian; Daniel Levy; Teri Manolio; Shanthi Mendis; George Mensah; Andrzej Pajak; Ronald J Prineas; K Srinath Reddy; Veronique L Roger; Wayne D Rosamond; Eyal Shahar; A Richey Sharrett; Paul Sorlie; Hugh Tunstall-Pedoe
Journal:  Circulation       Date:  2003-11-10       Impact factor: 29.690

2.  Epidemiologic assessment of the role of blood pressure in stroke. The Framingham study.

Authors:  W B Kannel; P A Wolf; J Verter; P M McNamara
Journal:  JAMA       Date:  1970-10-12       Impact factor: 56.272

3.  Resistant hypertension: a frequent and ominous finding among hypertensive patients with atherothrombosis.

Authors:  Dharam J Kumbhani; P Gabriel Steg; Christopher P Cannon; Kim A Eagle; Sidney C Smith; Kevin Crowley; Shinya Goto; E Magnus Ohman; George L Bakris; Todd S Perlstein; Scott Kinlay; Deepak L Bhatt
Journal:  Eur Heart J       Date:  2012-11-09       Impact factor: 29.983

4.  Verifying the stroke-free phenotype by structured telephone interview.

Authors:  J F Meschia; T G Brott; F E Chukwudelunzu; J Hardy; R D Brown; I Meissner; L J Hall; E J Atkinson; P C O'Brien
Journal:  Stroke       Date:  2000-05       Impact factor: 7.914

5.  Heart rate and cardiovascular mortality: the Framingham Study.

Authors:  W B Kannel; C Kannel; R S Paffenbarger; L A Cupples
Journal:  Am Heart J       Date:  1987-06       Impact factor: 4.749

6.  Concurrent and predictive validity of a self-reported measure of medication adherence.

Authors:  D E Morisky; L W Green; D M Levine
Journal:  Med Care       Date:  1986-01       Impact factor: 2.983

7.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

Review 8.  Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context.

Authors:  R Collins; R Peto; S MacMahon; P Hebert; N H Fiebach; K A Eberlein; J Godwin; N Qizilbash; J O Taylor; C H Hennekens
Journal:  Lancet       Date:  1990-04-07       Impact factor: 79.321

9.  Stroke--1989. Recommendations on stroke prevention, diagnosis, and therapy. Report of the WHO Task Force on Stroke and other Cerebrovascular Disorders.

Authors: 
Journal:  Stroke       Date:  1989-10       Impact factor: 7.914

10.  Benefits of antihypertensive pharmacologic therapy and blood pressure reduction in outcome trials.

Authors:  Ji-Guang Wang; Jan A Staessen
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Jan-Feb       Impact factor: 3.738

View more
  53 in total

Review 1.  Coronary heart disease risk factors and outcomes in the twenty-first century: findings from the REasons for Geographic and Racial Differences in Stroke (REGARDS) Study.

Authors:  Hemal Bhatt; Monika Safford; Stephen Glasser
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

Review 2.  Primary aldosteronism: a common cause of resistant hypertension.

Authors:  Gregory A Kline; Ally P H Prebtani; Alexander A Leung; Ernesto L Schiffrin
Journal:  CMAJ       Date:  2017-06-05       Impact factor: 8.262

3.  Is there an association between the prevalence of atrial fibrillation and severity and control of hypertension? The REasons for Geographic And Racial Differences in Stroke study.

Authors:  Hemal Bhatt; Christopher M Gamboa; Monika M Safford; Elsayad Z Soliman; Stephen P Glasser
Journal:  J Am Soc Hypertens       Date:  2016-05-30

4.  Obesity, African American Race, Chronic Kidney Disease, and Resistant Hypertension: The Step Beyond Observed Risk.

Authors:  Eric Judd; David A Calhoun
Journal:  Hypertension       Date:  2015-12-28       Impact factor: 10.190

Review 5.  Resistant Hypertension: Mechanisms and Treatment.

Authors:  Andrew Y Hwang; Eric Dietrich; Carl J Pepine; Steven M Smith
Journal:  Curr Hypertens Rep       Date:  2017-07       Impact factor: 5.369

6.  Differential Outcomes by Race and Ethnicity in Patients with Coronary Heart Disease: A Contemporary Review.

Authors:  Heidi Mochari-Greenberger; Lori Mosca
Journal:  Curr Cardiovasc Risk Rep       Date:  2015-05

7.  Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association.

Authors:  Robert M Carey; David A Calhoun; George L Bakris; Robert D Brook; Stacie L Daugherty; Cheryl R Dennison-Himmelfarb; Brent M Egan; John M Flack; Samuel S Gidding; Eric Judd; Daniel T Lackland; Cheryl L Laffer; Christopher Newton-Cheh; Steven M Smith; Sandra J Taler; Stephen C Textor; Tanya N Turan; William B White
Journal:  Hypertension       Date:  2018-11       Impact factor: 10.190

8.  Prevalence of electrocardiographic abnormalities based on hypertension severity and blood pressure levels: the Reasons for Geographic and Racial Differences in Stroke study.

Authors:  Hemal Bhatt; Christopher M Gamboa; Monika M Safford; Elsayed Z Soliman; Stephen P Glasser
Journal:  J Am Soc Hypertens       Date:  2016-06-27

9.  Longitudinal Effect of CPAP on BP in Resistant and Nonresistant Hypertension in a Large Clinic-Based Cohort.

Authors:  Harneet K Walia; Sandra D Griffith; Nancy Foldvary-Schaefer; George Thomas; Emmanuel L Bravo; Douglas E Moul; Reena Mehra
Journal:  Chest       Date:  2016-01-08       Impact factor: 9.410

Review 10.  Refractory Hypertension: A Novel Phenotype of Antihypertensive Treatment Failure.

Authors:  Tanja Dudenbostel; Mohammed Siddiqui; Suzanne Oparil; David A Calhoun
Journal:  Hypertension       Date:  2016-04-18       Impact factor: 10.190

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.